Skip to main content

Kennedy-Wilson Announces Redemption of Euro Notes

Tipranks - Fri Aug 8, 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Kennedy-Wilson ( (KW) ) has provided an announcement.

On August 7, 2025, Kennedy Wilson Europe Real Estate Limited announced its decision to redeem all of its outstanding 3.250% euro-denominated Notes due 2025 on October 3, 2025. The redemption will involve the principal amount of €300,000,000 along with accrued interest totaling €8,681,520, after which no Notes will remain outstanding. This move signifies a strategic financial decision by the company, potentially impacting its financial structure and signaling a shift in its debt management strategy.

The most recent analyst rating on (KW) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Kennedy-Wilson stock, see the KW Stock Forecast page.

Spark’s Take on KW Stock

According to Spark, TipRanks’ AI Analyst, KW is a Neutral.

The overall score reflects Kennedy-Wilson’s financial challenges, with significant leverage and negative profitability impacting the rating. However, strategic growth initiatives and debt reduction efforts provide a positive outlook. Technical indicators suggest moderate bullish momentum, while the dividend yield offers income potential despite valuation concerns.

To see Spark’s full report on KW stock, click here.

More about Kennedy-Wilson

Kennedy Wilson Europe Real Estate Limited, a wholly owned subsidiary of Kennedy-Wilson Holdings, Inc., operates in the real estate industry. The company focuses on managing and investing in real estate assets across Europe.

Average Trading Volume: 1,100,234

Technical Sentiment Signal: Sell

Current Market Cap: $1.02B

For an in-depth examination of KW stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.